Shaohui Deng
Overview
Explore the profile of Shaohui Deng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deng S, Hu L, Chen G, Ye J, Xiao Z, Guan T, et al.
Adv Mater
. 2025 Feb;
:e2419418.
PMID: 39955653
Although the combination of radiotherapy and immunotherapy is regarded as a promising clinical treatment strategy, numerous clinical trials have failed to demonstrate synergistic effects. One of the key reasons is...
2.
Yu L, Yan Y, Chu H, Deng S, Ye J, Wang G, et al.
BMC Urol
. 2025 Jan;
25(1):4.
PMID: 39794743
Background: To propose the bladder mucosal smoothness (BMS) grade and validate a predictive model including MRI parameters preoperatively that can evaluate the early recovery of urinary continence (UC) after laparoscopic...
3.
Zheng X, Deng S, Li Y, Luo Z, Gan Z, Zheng Z, et al.
Biomaterials
. 2025 Jan;
317:123065.
PMID: 39756272
Chronic diabetic wounds are a prevalent and severe complication of diabetes, contributing to higher rates of limb amputations and mortality. N6-methyladenosine (mA) is a common RNA modification that has been...
4.
Liu Y, Nie J, Huang Y, Yang Y, Su W, Zhang Y, et al.
Arch Oral Biol
. 2024 Dec;
170:106149.
PMID: 39643954
Objective: N6-methyladenosine (m6A) RNA dysregulation is crucial for cancer development. The study aimed to explore the effects of m6A modification in oral squamous cell carcinoma (OSCC) and its potential as...
5.
Ou J, Su D, Guan Y, Ge L, Deng S, Yan Y, et al.
Discov Oncol
. 2024 Nov;
15(1):619.
PMID: 39499440
Introduction: Desmoid tumors (DT) are rare, locally invasive tumors originating from connective tissue. Surgical intervention is no longer the standard treatment for DT, as systemic therapy gradually replaces it due...
6.
Guo S, Guan T, Ke Y, Lin Y, Tai R, Ye J, et al.
Biomaterials
. 2024 Oct;
315:122905.
PMID: 39471713
Amidst the therapeutic quandaries associated with triple-negative breast cancer (TNBC), an aggressive malignancy distinguished by its immune resistance and limited treatment avenues, the urgent need for innovative solutions is underscored....
7.
Hu L, Li T, Deng S, Gao H, Jiang Y, Chen Q, et al.
Biomaterials
. 2024 Sep;
314:122846.
PMID: 39317142
Tertiary lymphoid structures (TLSs) are known to enhance the prognosis of patients with colorectal cancer (CRC) by fostering an immunologically active tumor microenvironment (TME). Inducing TLS formation therapeutically holds promise...
8.
Shu F, Hao Y, Yan Y, Lu M, Ma L, Deng S, et al.
Medicina (Kaunas)
. 2024 Aug;
60(8).
PMID: 39202574
Renal angiomyolipoma (AML) without local invasion is generally considered benign. However, it may extend to the renal sinus, even the renal vein, or the inferior vena cava (IVC). In patients...
9.
Chen K, Yu L, Ge L, Deng S, Zhang F, Wang G, et al.
Surg Endosc
. 2024 Aug;
38(10):5891-5902.
PMID: 39168857
Background: To define the incidence and independent predictive factors of intraoperative adverse events (IOAEs) after minimally invasive radical nephrectomy and thrombectomy (RNAT) and to determine the impact of intraoperative adverse...
10.
Zhou Z, Deng S, Yan Y, Zhang F, Hao Y, Ge L, et al.
Beijing Da Xue Xue Bao Yi Xue Ban
. 2024 Jul;
56(4):673-679.
PMID: 39041564
Objective: To predict the 3-year cancer-specific survival (CSS) of patients with non-metastatic T renal cell carcinoma after surgery. Methods: A total of 336 patients with pathologically confirmed T N0-1M0 renal...